1 MAD associated with progeroid appearance and generalized lipodystrophy.

2 dherent skin, an aged appearance, and severe generalized lipodystrophy.

3                     Ten patients with either generalized lipodystrophy (8 patients) or Dunnigan's par

4          Leptin is an approved treatment for generalized lipodystrophy, a condition associated with s

5 versal feature of human and rodent models of generalized lipodystrophy and is also a common feature o

6 hat mutations in AGPAT2 may cause congenital generalized lipodystrophy by inhibiting triacylglycerol

7                                   Congenital generalized lipodystrophy (CGL) is a rare autosomal rece

8                                   Congenital generalized lipodystrophy (CGL) is a rare disorder chara

9 e exhibit many of the features of congenital generalized lipodystrophy (CGL), an autosomal recessive

10                                   Congenital generalized lipodystrophy (CGL), secondary to AGPAT2 mut

11 fied in individuals affected with congenital generalized lipodystrophy (CGL).

12 exhibit a syndrome that resembles congenital generalized lipodystrophy in humans.

13                                   Congenital generalized lipodystrophy is an autosomal recessive diso

14  of such disorders of liporegulation include generalized lipodystrophies, mutations of leptin and lep

15 observed either from birth, as in congenital generalized lipodystrophy, or later in life, as in famil

16 ibited MSTN signaling in a diabetic model of generalized lipodystrophy to analyze its effects on gluc

17 d cMAT are preserved in mice with congenital generalized lipodystrophy type 3.

18  Loss of rMAT occurs in mice with congenital generalized lipodystrophy type 4, whereas both rMAT and